Rinsho Kensa Volume 54, Issue 3 (March 2010)
Japanese

Treatment―guideline, outcome, prognosis:polycythemia vera Rie Imamura 1 , Takashi Okamura 1 1Division of Hematology and Oncology, Department of Medicine, Kurume University Scool of Medicine Keyword: JAK2 V617F , 血栓症 , 白血病転化 , 瀉血療法 , ヒドロキシウレア pp.281-286
Published Date 2010/3/15
DOI https://doi.org/10.11477/mf.1542102254
  • Abstract
  • Look Inside
  • Reference

Polycythemia vera is a subgroup of myeloproliferative neoplasms. The causal event is a gain-of function mutation of JAK2 gene(JAK2 V617F), which is found in up to 95% of PV cases. The goal of therapy is prevention of thrombosis and secondary leukemia. Risk-stratified therapeutic option is recommended;phlebotomy and low-dose aspirin for low risk patients, and low-dose aspirin and hydroxyurea for high risk patients.


Copyright © 2010, Igaku-Shoin Ltd. All rights reserved.

基本情報

04851420.54.3.jpg
臨床検査
54巻3号 (2010年3月)
電子版ISSN 1882-1367 印刷版ISSN 0485-1420 医学書院

関連文献

もっと見る

文献を共有